Dopavision Closes €12 Million Series A Round to Advance globenewswire.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from globenewswire.com Daily Mail and Mail on Sunday newspapers.
Libtayo (cemiplimab) approved by the European Commission for first-line treatment of patients with advanced non-small cell lung cancer with =50% PD-L1 expression Approval
TARRYTOWN, N.Y. and PARIS, June 25, 2021 /PRNewswire/
Approval based on a Phase 3 trial demonstrating Libtayo significantly improved overall survival compared to chemotherapy in advanced. | June 25, 2021
TARRYTOWN, N.Y. and PARIS, June 25, 2021 /PRNewswire/
Approval based on data from the largest trial to date in patients with advanced basal cell carcinoma previously treated with a hedgehog pathway inhibitor
Libtayo now approved by the European Commission for three advanced cancers
Regeneron Pharmaceuticals, Inc. (NASDAQ:
REGN) and Sanofi today announced that the European Commission (EC) has approved the PD-1 inhibitor Libtayo
® (cemiplimab) to treat adults with locally advanced or metastatic basal cell carcinoma (BCC) who have progressed on or are intolerant to a hedgehog pathway inhibitor (HHI).
BCC is the most common type of skin cancer worldwide, representing up to 80% of non-melanoma skin cancers, and incidence is increasing across many European countries. While the large majority of BCCs are caught early and easily cured with surgery and/or radiation, a small proportion of cases can develop into advanced BCC and penetrate deeper into surrounding tissues (locally